Context Therapeutics is trading 22.1% down at $0.54 in pre-market, extending a sharp after-hours selloff after reporting its Q2 2026 financial results. * The company announced a net loss of $14.6 million for Q2 2026, missing analysts' consensus EPS estimates by $0.05. * Context also revealed the discontinuation of its CT-95 development program, choosing to prioritize CTIM-76 and CT-202. * Shares fell approximately 24.2% to $0.53 during after-hours trading on August 5, 2026, as investors reacted to the news.